ZYBERNO
Stock Report
Updated Sep 1, 2026

Lantern Pharma Inc. (LTRN)

Healthcare • NASDAQ

$2.03

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
8.0/100
POOR BUSINESS
Lantern Pharma Inc. (LTRN) scores 8/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-456.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-796.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Lantern Pharma Inc. (LTRN) stock report — Zyberno Score 8/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, LTRN generated -$15.68M in Owner Earnings. Capital was deployed as follows: $1.72K invested in capital expenditures. Reinvestment rate: 0.1%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.03
Market Cap:$25.22M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$22.88M

Price Action & Momentum (1)

% of 52-Week High:43.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-184.3%
Reinvestment Rate:0.1%
Fundamental Growth Rate (g):-0.8%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$63.78
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-57.4%
Latest Earnings Filed:2026-08-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.96x
Quick Ratio:1.96x
Cash Ratio:1.54x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:4,136,407.00
Cash And Cash Equivalents:6,660,170.00
Long Term Debt:$39.72K
Net Debt:-$2.34M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$15.47M

Bottom Line Performance (3)

-$18.65M
Income Before Tax:$16.98M
Ebitda Ttm:-15,449,340.00

Operating Expenses (5)

Operating Expenses:15,465,899.00
R And D Expense:8,697,520.00
Sga Expense:6,768,379.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$8.60M
Current Assets:$8.46M
Ppe Net:24,271.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:11,819,601.00
Current Liabilities:4,322,512.00
Long Term Debt:$39.72K
Short Term Debt:$4.28M

Equity & Capital (3)

Equity:-$3.22M
Retained Earnings:-$103.55M
Common Stock:25,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:4,282,797.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:198,939.00
C. Cash Flow Analysis

Operating Activities (2)

-$15.07M-$15.08M

Investment Activities (2)

Investing Cash Flow:$4.25M
Capital Expenditures Ttm:1,715.00

Financing Activities (3)

Financing Cash Flow:$526.46K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:30,722.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:16,559.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.62
-$1.62
Earnings Per Share Ttm:-$1.50

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.26

Book Value & Capital (2)

Book Value Per Share:-$0.26
Cash Per Share:0.54

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$15.68M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.1%
Fundamental Growth Rate (g):-0.8%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-47.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:LTRN
Company Name:Lantern Pharma Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:12.42M
Shares Outstanding Basic:12.42M
Shares Outstanding Diluted:12.42M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 03:15:47 UTC
Data Timestamp:2026-08-20T11:01:07.526936
Scroll to Top